The mechanism of disease, as well as the mechanism of action (MOA) for any particular drug, is the primary goal of scientific publications, and a secondary goal of medical publications and regulatory submissions. The chapters in this book on MOA disclose the role of MOA in regulatory ...
Described here are neural networks capable of predicting a drug's mechanism of action from its pattern of activity against a panel of 60 malignant cell lines in the National Cancer Institute's drug screening program. Given six possible classes of mechanism, the network misses the correct category...
Fig. 4. Mechanism of emodin's multi-drug resistance in breast cancer. Download: Download high-res image (317KB) Download: Download full-size image Fig. 5. Mechanism of emodin's combination of drugs in breast cancer. Compared with traditional chemotherapeutic drugs, traditional Chinese medicine (...
5-Fluorouracil (5-FU) is widely used in the treatment of cancer. Over the past 20 years, increased understanding of the mechanism of action of 5-FU has led to the development of strategies that increase its anticancer activity. Despite these advances, drug resistance remains a significant limit...
In sum, we reveal for the first time the mechanism of cancer drug addiction in ALK-positive ALCL and the benefit of scheduled intermittent dosing in high-risk patient-derived tumors in vivo. This is a preview of subscription content, access via your institution Access options Subscribe to ...
Even if resistance can develop to different drugs, the underlying mechanisms may be similar. Thus, instead of simply distinguishing resistance by agent, we attempted to classify drug resistance by mechanism. We summarized four major mechanisms (Fig.1) from the published literature: 1) abnormalities ...
Finally, the mechanism of action for atezolizumab involves the PD-L1 protein, which can be expressed on tumor cells and tumor-infiltrating immune cells. According to the poster, binding PD-L1 to its inhibitory receptors programmed cell death protein 1 (PD-1) and B7.1 on T cells ...
Five of the 10 drugs (50%) act on a novel target (ibrutinib, brentuximab vedotin, ruxolintinib, cabozantinib, and eculizumab), whereas the other 5 (50%) are next-in-class drugs with a mechanism of action similar to a previously approved drug. The median cost of development of a single...
drug mechanism of action, and is biologically interpretable. Inhibition of MEK leads to cystic reorganization of organoids and increases expression ofLGR5, while inhibition of mTOR induces IGF1 receptor signaling. In conclusion, we identify shared axes of variation for colorectal cancer organoid morphol...
Evidence has recently emerged that many clinical cancer drug combinations may derive their efficacy from independent drug action (IDA), where patients only receive benefit from the single most effective drug in a drug combination. Here we present IDAComb